{"id":126027,"date":"2026-07-09T08:44:40","date_gmt":"2026-07-09T08:44:40","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/126027\/"},"modified":"2026-07-09T08:44:40","modified_gmt":"2026-07-09T08:44:40","slug":"india-gets-novo-nordisks-once-weekly-insulin-injection-awiqli-for-adults-with-diabetes","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/126027\/","title":{"rendered":"India gets Novo Nordisk&#8217;s once-weekly insulin injection Awiqli for adults with diabetes"},"content":{"rendered":"<p class=\"content\">Danish pharmaceutical major Novo Nordisk on Thursday launched its once-weekly basal insulin injection, Awiqli, in India for the treatment of diabetes in adults, marking the country&#8217;s entry as the seventh market to introduce the therapy.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/Diabetes_India_1783584559754_1783584559898_a9d3c148-1b9c-42c1-8c12-b2e90d44d21a.jpg\" alt=\"Awiqli is designed for people with Type 1 and Type 2 diabetes mellitus. (Shutterstock)\" title=\"Awiqli is designed for people with Type 1 and Type 2 diabetes mellitus. (Shutterstock)\" width=\"360\" height=\"202\" loading=\"eager\"\/>Awiqli is designed for people with Type 1 and Type 2 diabetes mellitus. (Shutterstock)<\/p>\n<p class=\"content \">The company said Awiqli is designed for people with Type 1 and Type 2 diabetes mellitus and replaces the need for a daily basal insulin injection with a once-a-week dose. This reduces the annual number of injections from 365 to just 52.<\/p>\n<p class=\"content \">&#8220;It is a modern therapy, and we (India) are the seventh country to launch (the injection),&#8221; Novo Nordisk India Managing Director, Vikrant Shrotriya told PTI, adding that the injection will be introduced in two pens &#8211; 700 units and 2,100 units, with a per unit cost of  \u20b93.73.<\/p>\n<p class=\"content \">Also Read | <a class=\"backlink\" target=\"_blank\" href=\"https:\/\/www.hindustantimes.com\/business\/novo-nordisk-cuts-ozempic-price-in-india-amid-generics-onslaught-101774972576508.html\" data-vars-page-type=\"story\" data-vars-link-type=\"Manual\" data-vars-anchor-text=\"Novo Nordisk cuts Ozempic price in India amid generics onslaught\" rel=\"nofollow noopener\">Novo Nordisk cuts Ozempic price in India amid generics onslaught<\/a><\/p>\n<p class=\"content \">With the reduction of the number of injections required for diabetic patients, the company stated that the barriers to needing insulin will be reduced.<\/p>\n<p class=\"content \">Shrotriya noted that in usual therapies patients with diabetes normally will have to take insulin injection every day, which leads to people actually denying insulin as &#8220;they think that they have to take every day and they have to take lifelong&#8221;.<\/p>\n<p class=\"content \">But with Awiqli, that barrier is reduced, and patients get greater control.<\/p>\n<p class=\"content \">Also Read | <a class=\"backlink\" target=\"_blank\" href=\"https:\/\/www.hindustantimes.com\/lifestyle\/health\/doctor-explains-how-climate-change-rising-temperatures-may-influence-your-diabetes-patterns-suggests-safety-measures-101775556729866.html\" data-vars-page-type=\"story\" data-vars-link-type=\"Manual\" data-vars-anchor-text=\"Doctor explains how climate change, rising temperatures may influence your diabetes patterns\" rel=\"nofollow noopener\">Doctor explains how climate change, rising temperatures may influence your diabetes patterns<\/a><\/p>\n<p class=\"content \">&#8220;We believe Awiqli will reduce the psychological and physical barriers to insulin initiation, and ultimately help more people achieve better control and a better quality of life,&#8221; the managing director added.<\/p>\n<p class=\"content \">The injection will be available across the country through 4,5000 distributors.<\/p>\n<p class=\"content \">(With inputs from PTI)<\/p>\n","protected":false},"excerpt":{"rendered":"Danish pharmaceutical major Novo Nordisk on Thursday launched its once-weekly basal insulin injection, Awiqli, in India for the&hellip;\n","protected":false},"author":2,"featured_media":126028,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[27733,61591,18205,272,61443],"class_list":["post-126027","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-awiqli","tag-basal-insulin-injection","tag-diabetes-treatment","tag-novo-nordisk","tag-type-1-and-type-2-diabetes"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116889142227639485","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/126027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=126027"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/126027\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/126028"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=126027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=126027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=126027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}